



King's Research Portal

DOI:

[10.1093/annonc/mdy244](https://doi.org/10.1093/annonc/mdy244)

Document Version

Other version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Massard, C., Azaro, A., Soria, J. C., Lassen, U., Le Tourneau, C., Sarker, D., Smith, C., Ohnmacht, U., Oakley, G., Patel, B. K. R., Yuen, E. S. M., Benhadji, K. A., & Rodon, J. (2018). First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. *Annals of Oncology*, 29(9), 1911-1917. <https://doi.org/10.1093/annonc/mdy244>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

First-in-human study of LY3039478, an Oral Notch signaling inhibitor in advanced or metastatic cancer

Supplementary Data

Definitions

A dose-limiting toxicity was defined as an AE during cycle 1 that is related to LY3039478 and that fulfills any one of the following criteria using the NCI CTCAE v 4.0: ≥ 3 CTCAE grade 3 nonhematological toxicity (exceptions made for nausea, vomiting, or constipation that lasts <72 hours and can be controlled with treatment; transient grade 3 elevations of alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]), CTCAE grade 4 hematological toxicity of >5 days duration, any febrile neutropenia, grade 3 thrombocytopenia with bleeding or grade 4 thrombocytopenia, and other significant toxicity deemed to be dose limiting by investigator.

Immunoreactivity for the NICD fragment: A case was adjudicated positive for if equal or more than 10% of the tumor cells demonstrated specific nuclear staining with 1+ or greater intensity, based on cutoff established previously for the assay using transfected cell lines, known constitutionally mutationally active cell lines, and cell lines with no known Notch pathway activation to generate NICD fragments recognized by the proprietary IHC reagent antibodies.

List of 18 genes Notch signaling analyzed:

Hairy and enhancer of split-1 (Hes 1), Hes 2, Hes 3, Hes 4, Hes 5, Hes 6, Hes 7, hairy/enhancer of split related with YPRW motif (Hey 1), Hey 2, Hey L, olfactomedin 4 (OLFM 4), atonal bHLH transcription factor 1 (ATOH 1), deltex E3 ubiquitin ligase 1 (DTX1), DTX2, Notch-regulated ankyrin repeat (NRARP), V-MYC Aavian

Massard et al., Supplementary Data

myelocyomatosis viral oncogene homolog (MYC), V- Myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog (MYCN), and Cyclin D1 (CCND1).

Supplementary Table 1. Summary of Dose-Limiting Toxicities

Cohort (Dose)	Number of DLTs	Description of DLT	Maximum CTCAE Grade
Cohort 4 (20 mg)	1	Thrombocytopenia with bleeding	4
Cohort 5 (30 mg)	1	Thrombocytopenia with bleeding	4
Cohort 7 (60 mg)	1	Thrombocytopenia	4
Cohort 9 (100 mg)	1	Nausea not manageable with medical treatment, fatigue	3
	1	Colitis	3

Supplementary Table 2. Serious Adverse Events (Possibly Drug-Related), and Discontinuations Occurring in the Dose Confirmation Phase

	Adverse Event	Total (N=55) n (%)
Gastrointestinal	Diarrhea	7 (12.7)
	Colitis	3 (5.5)
	Nausea	2 (3.6)
	Anal Abscess	1 (1.8)
	Rectal Abscess	1 (1.8)
	Vomiting	1 (1.8)
	Hepatocellular Injury	1 (1.8)
Respiratory	Bronchitis	1 (1.8)
	Pulmonary Artery Aneurysm	1 (1.8)
General	Asthenia	2 (3.6)
	Pyrexia	2 (3.6)
	Abdominal Pain	1 (1.8)
	Hypotension	1 (1.8)
	Renal Failure	1 (1.8)
Metabolism Related	Decreased Appetite	1 (1.8)
Skin and Subcutaneous	Squamous Cell Carcinoma	1 (1.8)
	Squamous Cell Carcinoma of Skin	1 (1.8)
Discontinuations due to Study Drug-Related TEAEs	Diarrhea	2 (3.6)
	Nausea	1 (1.8)
	Decrease in Platelet Count	1 (1.8)

Supplementary Table 3. JJCA Mean PK Parameters Following Multiple Oral LY3039478 Doses of 2.5 to 100 mg in part A and B Patients with Intensive PK Sampling

Geometric Mean (%CV)										
Day 22 (Dose #10)										
	Part A								Part B	Part A
	2.5 mg	5 mg	10 mg	20 mg	30 mg	45 mg	60 mg	75 mg	75 mg	100 mg
N^a	2/2 ^e	3/3	4/3	6/6	5/5	5/5	5/4	4/4	6/4	5/5
t_{max}^b (h)	1.00- 1.00	2.00 (0.33- 2.00)	2.00 (1.00- 2.00)	2.00 (1.00- 4.00)	2.00 (1.00- 4.00)	1.00 (1.00- 2.03)	1.00 (0.50- 2.42)	2.05 (2.00- 4.00)	2.00 (0.98- 4.00)	1.00 (1.00-2.00)
C_{max} (ng/mL)	23.7- 24.1	38.0 (34)	81.9 (87)	175 (28)	191 (60)	522 (28)	516 (57)	444 (55)	531 (38)	770 (72)
AUC₍₀₋₄₈₎ (ng•h/mL)	92.1- 120	290 (33)	585 (90)	1170 (38)	1290 (71)	3220 (57)	2530 (37)	3350 (78)	2750 (25)	3900 (90)
t_{1/2}^c (h)	6.10- 6.11	6.32 (6.00- 6.74)	5.83 (4.72- 6.79)	5.76 (4.64- 7.09)	6.03 (5.01- 8.35)	5.74 (5.31- 7.12)	5.44 (4.62- 7.13)	5.19 (4.77- 5.54)	4.85 (3.83- 5.76)	5.39 (5.04-5.68)
R_A^d (ratio)	1.58- 1.92	1.03 (15)	1.43 (5)	1.10 (16) ^g	0.911 (19)	2.14 (44) ^e	0.972 (12)	0.516- 1.20 ^f	1.04 (53)	0.789 (71) ^g

^a Two N values reported. First N value is for C_{max} and t_{max}, while second N value is for remaining parameters that are dependent on terminal phase of PK profile. Parameters dependent on terminal phase only reported when 24hr time point is available and when $[(AUC_{(0-\infty)} - AUC_{last}) / AUC_{0-\infty}] * 100 \leq 15\%$.

^b Median (range)

^c Geometric mean (range)

^d Accumulation ratio AUC (0-24) [Day 22]/AUC(0-24) [Day 1]

^e N=4; one patient's RA not calculated since 75 mg was accidentally administered as Dose #1.

^f Range reported when N=2.


^g N=4.

Supplementary Table 4. Mean PK Parameters Following Single Oral LY3039478 Doses of 50 to 75 mg in part B Patients with Sparse PK Sampling


Geometric Mean (%CV)		
Day 1 (Dose #1)		
	50 mg	75 mg
N	27	13
t_{max}^a (h)	2.00 (0.50-4.00)	1.92 (1.00-6.00)
C_{max} (ng/mL)	490 (61)	672 (58)
AUC(0-4) (ng•h/mL)	1150 (54)	1620 (56)

^a Median (range)


Supplementary Figure 1. Dose schedule of LY3039478



Supplementary Figure 2. Effect of LY3039478 on GI tract




Supplementary Figure 3. NICD Activation of Notch Receptor 1. The percentage of each cancer category staining positive for Notch 1 NICD is presented




^aPopulation in part B was selected for notch alterations

Supplementary Figure 4. Fold Change from Baseline Plasma Amyloid-Beta with corresponding 90% confidence interval A. Day 1. B. Day 22




Supplementary Figure 5. Patient Scans

72-year-old female patient with infiltrating ductal breast carcinoma



33-year-old male patient with adenoid cystic carcinoma



59-year-old female patient with abdomen (non-GIST) leiomyosarcoma

